Deliryumda Psikofarmakolojik Yaklaşımlar
Özet
Deliryum, hastanede yatan hastaların %42'sini etkileyen, bilincin ve dikkatin akut bozulmasıyla seyreden önemli bir nöropsikiyatrik bozukluktur. Ancak vakaların %55-80'i klinik ekiplerce tanınmamakta; bu durum uzamış yatış süresi, artan mortalite ve demans gibi ciddi sonuçlara yol açmaktadır. Güncel yaklaşım risk etkenlerini önceden saptayıp farmakolojik olmayan çok bileşenli müdahalelerle (örneğin HELP modeli) deliryumu önlemektir, zira ilaçların deliryumu önlemedeki kanıtları yetersizdir. Önlemede antipsikotikler ve asetilkolin esteraz inhibitörleri önerilmezken; dahili hastalarda melatonin (ramelteon) ve yoğun bakım hastalarında deksmedetomidin deliryum insidansını azaltmada faydalı olabilir. Deliryum geliştikten sonra ise farmakolojik tedavilerin etkinliği kanıta dayalı olarak sınırlıdır ve bu ilaçlar sadece hastanın kendine veya çevreye zarar verme riski (şiddetli ajitasyon) varsa tercih edilmelidir. Klinik pratikte en sık kullanılan ilaç haloperidol olmakla birlikte, daha az yan etki profiline sahip risperidon, olanzapin ve ketiapin gibi atipik antipsikotikler de kısa süreli (3-5 gün) uygulanmaktadır. Yoğun bakımdaki deliryum tedavisinde solunum depresyonu yapmayan deksmedetomidin de hemodinamisi stabil hastalarda umut verici bir seçenektir; alkol yoksunluğu haricinde ise benzodiyazepinlerden kaçınılmalıdır. Sonuç olarak, deliryum yönetiminde öncelik daima farmakolojik olmayan yaklaşımlarda olmalı, ilaç tedavileri ise fikir birliği tam olmasa da sadece zorunlu durumlarda kısa süreli kullanılmalıdır.
Delirium is a significant neuropsychiatric disorder affecting 42% of hospitalized patients, characterized by acute impairment of consciousness and attention. However, 55-80% of cases remain unrecognized by clinical teams, leading to severe consequences such as prolonged hospitalization, increased mortality, and dementia. The current approach focuses on identifying risk factors beforehand and preventing delirium through multicomponent non-pharmacological interventions (e.g., the HELP model), as evidence for pharmacological prevention remains insufficient. While antipsychotics and acetylcholine esterase inhibitors are not recommended for prevention, melatonin (ramelteon) in medical patients and dexmedetomidine in intensive care patients may help reduce delirium incidence. Once delirium develops, the efficacy of pharmacological treatments is limited by evidence, and these medications should only be preferred if there is a risk of harm to the patient or others (severe agitation). Although haloperidol is the most commonly used drug in clinical practice, atypical antipsychotics like risperidone, olanzapine, and quetiapine, which have a lower side-effect profile, are also administered for short durations (3-5 days). In the treatment of ICU delirium, dexmedetomidine, which does not cause respiratory depression, stands out as a promising option in hemodynamically stable patients, whereas benzodiazepines should generally be avoided except in cases of alcohol withdrawal. Consequently, priority in delirium management must always be given to non-pharmacological approaches, and drug treatments should be used briefly only in mandatory situations, despite the ongoing lack of a complete consensus.
Referanslar
Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006;35(4):350-64. doi:10.1093/ageing/afl005.
Zalon ML, Sandhaus S, Kovaleski M, et al. Hospitalized older adults with established delirium: recognition, documentation, and reporting. J Gerontol Nurs. 2017;43(3):32-40. doi: 10.3928/00989134-20161109-01.
Han JH, Zimmerman EE, Cutler N, et al. Delirium in older emergency department patients: recognition, risk factors, and psychomotor subtypes. Acad Emerg Med. 2009;16(3):193-200. doi: 10.1111/j.1553-2712.2008.00339.x.
Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383:911–22. doi:10.1016/S0140-6736(13)60688-1.
Iglseder B, Frühwald T, Jagsch C. Delirium in geriatric patients. Wien Med Wochenschr. 2022;172(5-6):114-121. doi:10.1007/s10354-021-00904-z.
Garcez FB, Avelino-Silva TJ, Castro REV, et al. Delirium in older adults. Geriatr Gerontol Aging. 2021;15:e0210032. doi:10.53886/gga.e0210032.
Kim MS, Rhim HC, Park A, et al. Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis. J Psychiatr Res. 2020;125:164-176. doi: 10.1016/j.jpsychires.2020.03.012.
Gilmore ML, Wolfe DJ. Antipsychotic prophylaxis in surgical patients modestly decreases delirium incidence--but not duration--in high-incidence samples: a meta-analysis. Gen Hosp Psychiatry. 2013;35(4):370-5. doi: 10.1016/j.genhosppsych.2012.12.009.
Neufeld KJ, Yue J, Robinson TN, et al. Antipsychotic Medication for Prevention and Treatment of Delirium in Hospitalized Adults: A Systematic Review and Meta-Analysis. J Am Geriatr Soc. 2016;64(4):705-14. doi: 10.1111/jgs.14076.
Thanapluetiwong S, Ruangritchankul S, Sriwannopas O, et al. Efficacy of quetiapine for delirium prevention in hospitalized older medical patients: a randomized double-blind controlled trial. BMC Geriatr. 2021;21(1):215. doi: 10.1186/s12877-021-02160-7.
NICE (2010) Delirium:diagnosis,prevention and management. National Clinical Guideline Centre London, Epidemiyology, p. 72.
Zaslavsky A, Haile M, Kline R, et al. Rivastigmine in the treatment of postoperative delirium: a pilot clinical trial. Int J Geriatr Psychiatry. 2012;27(9):986-8. doi: 10.1002/gps.2801.
Chen S, Shi L, Liang F, et al. Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials. Mol Neurobiol. 2016;53(6):4046-4053. doi: 10.1007/s12035-015-9350-8.
Khaing K, Nair BR. Melatonin for delirium prevention in hospitalized patients: A systematic review and meta-analysis. J Psychiatr Res. 2021;133:181-190.doi: 10.1016/j.jpsychires.2020.12.020.
Hatta K, Kishi Y, Wada K, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014;71(4):397-403. doi: 10.1001/jamapsychiatry.2013.3320.
Mo Y, Zimmermann AE. Role of dexmedetomidine for the prevention and treatment of delirium in intensive care unit patients. Ann Pharmacother. 2013 Jun;47(6):869-76. doi: 10.1345/aph.1AR708.
Ng KT, Shubash CJ, Chong JS. The effect of dexmedetomidine on delirium and agitation in patients in intensive care: systematic review and meta-analysis with trial sequential analysis. Anaesthesia. 2019;74(3):380-392. doi: 10.1111/anae.14472.
Maldonado JR. Acute Brain Failure: Pathophysiology, Diagnosis, Management, and Sequelae of Delirium. Crit Care Clin. 2017;33(3):461-519. doi: 10.1016/j.ccc.2017.03.013.
Hshieh TT, Yang T, Gartaganis SL, et al. Hospital Elder Life Program: Systematic Review and Meta-analysis of Effectiveness. Am J Geriatr Psychiatry. 2018;26(10):1015-1033. doi: 10.1016/j.jagp.2018.06.007.
Wu YC, Tseng PT, Tu YK, et al. Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis. JAMA Psychiatry. 2019;76(5):526-535. doi:10.1001/jamapsychiatry.2018.4365.
Neerland BE, Neufeld KJ, Slooter AJC. Pharmacological Management of Delirium. JAMA Psychiatry. 2019;76(9):983. doi:10.1001/jamapsychiatry.2019.1513
Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299.
Bolton C, Thilges S, Lane C, et al. Post-traumatic Stress Disorder Following Acute Delirium. J Clin Psychol Med Settings. 2021;28(1):31-39. doi: 10.1007/s10880-019-09689-1.
Egberts A, Alan H, Ziere G, et al. Antipsychotics and Lorazepam During Delirium: Are We Harming Older Patients? A Real-Life Data Study. Drugs Aging. 2021;38(1):53-62. doi: 10.1007/s40266-020-00813-7.
Inouye SK, Marcantonio ER, Metzger ED. Doing Damage in Delirium: The Hazards of Antipsychotic Treatment in Elderly Persons. Lancet Psychiatry. 2014;1(4):312-315. doi: 10.1016/S2215-0366(14)70263-9.
Devlin JW, Bhat S, Roberts RJ, et al. Current perceptions and practices surrounding the recognition and treatment of delirium in the intensive care unit: a survey of 250 critical care pharmacists from eight states. Ann Pharmacother. 2011;45(10):1217-29. doi: 10.1345/aph.1Q332.
Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. Palliat Support Care. 2015;13(4):1079-85. doi: 10.1017/S1478951514001059.
Young J, Murthy L, Westby M, et al. Guideline Development Group. Diagnosis, prevention, and management of delirium: summary of NICE guidance. BMJ. 2010;341:c3704. doi: 10.1136/bmj.c3704.
Thom RP, Mock CK, Teslyar P. Delirium in hospitalized patients: Risks and benefits of antipsychotics. Cleve Clin J Med. 2017;84(8):616-622. doi: 10.3949/ccjm.84a.16077.
Agar MR, Lawlor PG, Quinn S, et al. Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial. JAMA Intern Med. 2017;177(1):34-42. doi: 10.1001/jamainternmed.2016.7491.
Skrobik Y, Duprey MS, Hill NS, et al. Low-Dose Nocturnal Dexmedetomidine Prevents ICU Delirium. A Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med. 2018;197(9):1147-1156. doi:10.1164/rccm.201710-1995OC.
Zhang DF, Su X, Meng ZT, et al. Impact of Dexmedetomidine on Long-term Outcomes After Noncardiac Surgery in Elderly: 3-Year Follow-up of a Randomized Controlled Trial. Ann Surg. 2019;270(2):356-363. doi:10.1097/SLA.0000000000002801.
Hov KR, Neerland BE, Undseth Ø, et al. The Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID: a randomised placebo-controlled trial. Int J Geriatr Psychiatry. 2019;34(7):974-981. doi:10.1002/gps.5098.
